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Abstract Unique unaffected skeletal muscle fibres, un-
like necrotic torso and limb muscles, may pave the way
for a more detailed understanding of the molecular patho-
genesis of inherited neuromuscular disorders and help to
develop new treatment strategies for muscular dystro-
phies. The sparing of extraocular muscle in Duchenne
muscular dystrophy is mostly attributed to the special
protective properties of extremely fast-twitching small-
diameter fibres, but here we show that distal muscles also
represent a particular phenotype that is more resistant to
necrosis. Immunoblot analysis of membranes isolated
from the well established dystrophic animal model mdx
shows that, in contrast to dystrophic limb muscles, the toe
musculature exhibits an up-regulation of the autosomal
dystrophin homologue utrophin and a concomitant rescue
of dystrophin-associated glycoproteins. Thus distal mdx
muscle groups provide a cellular system that naturally
avoids myofibre degeneration which might be useful in
the search for naturally occurring compensatory mecha-
nisms in inherited skeletal muscle diseases.
Introduction
Duchenne muscular dystrophy (DMD) represents the
most common inherited neuromuscular disorder and
eventually affects almost all major muscle groups. Early
muscle weakness involves more proximal than distal fi-
bres and initially alters mostly the muscle of the lower
extremities and torso. At an intermediate stage, when
ambulation is lost, DMD patients can still conduct limit-
ed muscle movements with their forearms and hand mus-
cles. Although end-stage DMD also severely weakens
hand muscles, a graded dystrophic response of individual
groups of skeletal muscle fibres clearly exists during the
natural time course of this genetic disorder (Engel et al.
1994). In contrast to a wealth of information published
on the sparing of fast-twitching and small-diameter ex-
traocular DMD muscle fibres (Andrade et al. 2000), the
adaptive processes involved in the prolonged protection
of more distal muscle cells from Ca2+-induced myone-
crosis are not well understood.
In order to address this question, we performed a
comparative immunoblot analysis of leg and toe muscle
specimens from the naturally occurring dystrophic mdx
mouse, an established model system of DMD pathology
(Allamand and Campbell 2000). The suitability of mdx
muscle fibres for research purposes is attested by its
wide application in testing novel therapeutic strategies 
to ameliorate the symptoms of muscular dystrophy
(Badalamente and Stracher 2000; Wehling et al. 2001).
In analogy to DMD patients, the mdx skeletal muscle fi-
bres are missing the Dp427 isoform of a protein named
dystrophin due to primary genetic abnormality (Sicinski
et al. 1989). The absence of this membrane cytoskeletal
component causes the loss of several sarcolemmal glyco-
proteins, which is postulated to interrupt the proper link-
age between the extracellular matrix and the membrane
cytoskeleton, thereby rendering muscle cells more sus-
ceptible to necrosis (Ohlendieck 1996). Dystrophin-asso-
ciated glycoproteins are represented by various isoforms
of peripheral proteins termed dystroglycans, sarcogly-
cans, syntrophins, dystrobrevins and sarcospan (Culligan
et al. 1998).
Limb muscle fibres from mdx mice exhibit segmental
necrosis, are more susceptible to stretch-induced injury
and osmotic shock, and show Ca2+-induced net degrada-
tion of muscle proteins (Allamand and Campbell 2000).
In both mdx and DMD leg muscle specimens, it has been
demonstrated that deficiency in Dp427 does not trigger a
general degradation of surface glycoproteins, but specifi-
cally causes a reduction in dystrophin-associated glyco-
proteins (Ohlendieck 1996). Therefore this study mea-
sured the relative expression levels of dystroglycans and
sarcoglycans in the microsomal membrane fraction,
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which gives a good indication of the dystrophic status of
a particular group of skeletal muscle fibres.
Materials and methods
Dystrophin-deficient mdx mice, which are missing the Dp427 dys-
trophin isoform due to a point mutation in exon 23 (Sicinski et al.
1989), were obtained from Jackson Laboratory (Bar Harbor, Me.).
In order to compare the relative expression levels of members of
the dystrophin–glycoprotein complex in mdx leg and toe muscles
by immunoblotting, established protocols for the isolation of mi-
crosomal membranes were employed (Ohlendieck et al. 1991).
Since toe muscle fibres represent only a minute amount of tissue,
four preparations of skeletal muscles pooled from ten animals
each time were used in our analysis. Gel electrophoretic separa-
tion, transfer of proteins to nitrocellulose sheets, incubation with
primary and secondary antibodies, as well as enhanced chemilu-
minescence, were carried out by previously optimised methods
(Culligan et al. 2001). Antibodies were obtained from Novocastra
Laboratories, Newcastle upon Tyne, UK (mAb NCL-43 to β-dys-
troglycan and mAb DYS-2 to the carboxy-terminus of Dp427),
Upstate Biotechnology, Lake Placid, N.Y. (mAb VIA41 to α-dys-
troglycan) and Affinity Bioreagents, Golden, Colo. (mAb 20A 
to the α2-dihydropyridine receptor). A polyclonal antibody to 
α-sarcoglycan was characterised as previously described (Culligan
et al. 2001) and a polyclonal antibody directed against the car-
boxy-terminal domain of full-length utrophin was a generous gift
from S. Winder (University of Glasgow). Densitometric scanning
of immuno-decorated blots was performed on a Molecular Dy-
namics 300S computing densitometer (Sunnyvale, Calif.) with Im-
ageQuant V3.0 software. Peroxidase-conjugated secondary anti-
bodies were purchased from Boehringer Mannheim (Lewis, East
Sussex), Immobilon-P nitrocellulose was from Millipore Corpora-
tion (Bedford, Mass.), and all other chemicals were of analytical
grade and purchased from Sigma Chemical (Poole, Dorset). Tissue
preparation, cryo-sectioning, histochemical staining and microsco-
py were performed as previously described in detail by Ohlen-
dieck and Campbell (1991).
Results
A well established feature of deficiency in the sub-sarco-
lemmal component dystrophin is a drastic reduction in
numerous muscle surface glycoproteins. However, as il-
lustrated in Fig. 1, our comparative immunoblot analysis
demonstrates that this secondary effect on the relative
expression of dystrophin-associated glycoproteins does
not occur in mdx toe muscle as compared with leg mus-
cle. Although both tissues are lacking the dystrophin iso-
form Dp427 (Fig. 1a), the expression levels of α-sarco-
glycan (Fig. 1e) and α/β-dystroglycan (Fig. 1f, g) are
relatively comparable to normal muscle fibre. Important-
ly, the autosomal dystrophin-homologue named utrophin
is up-regulated in mdx toe muscles (Fig. 1b). Laminin
expression was not found to be markedly changed in the
various muscle specimens studied (Fig. 1d). For control
purposes, the relative expression levels of the α2-subunit
of the dihydropyridine receptor are shown (Fig. 1c).
Similar amounts of this highly glycosylated marker pro-
tein of the muscle cell periphery were found in microso-
mes isolated from normal, mdx leg and mdx toe muscle
homogenates. Thus the observed differences in the rela-
tive density of dystrophin-associated glycoproteins be-
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Fig. 1a–g Up-regulation of utrophin and rescue of dystrophin-
associated glycoproteins in dystrophin-deficient mdx toe muscle,
as demonstrated by comparative immunoblot analysis of microso-
mes isolated from normal mouse skeletal muscle (lane 1), mdx leg
muscle (lane 2), and mdx toe muscle (lane 3). Shown are identical
nitrocellulose blots labelled with antibodies to the Dp427 isoform
of dystrophin (a), the Up395 isoform of utrophin (b), the α2-sub-
unit of the dihydropyridine receptor (α2-DHPR) (c), laminin (d),
α-sarcoglycan (e), α-dystroglycan (f), and β-dystroglycan (g). In
panels (a) to (g), the expression of α2-DHPR was used for internal
standardisation of the immunoblotting procedure. Immuno-deco-
rated protein bands are marked by arrow heads
Fig. 2a–c Relative expression of utrophin, dystroglycan and the di-
hydropyridine receptor in normal, mdx leg and mdx toe muscle fi-
bres. Shown is the densitometric analysis of the immuno-decoration
of the α2-subunit of the dihydropyridine receptor (α2-DHPR) (a),
the Up395 isoform of utrophin (b) and β-dystroglycan (c) (n=4)
tween mdx leg and toe muscle groups is a reliable mea-
surement and is not a result of the subcellular fraction-
ation methodology. As shown in Fig. 2, the densitomet-
ric analysis of the immuno-decoration of utrophin and 
β-dystroglycan shows the up-regulation of utrophin and
partial rescue of dystroglycan expression. The immuno-
decoration intensity of the dihydropyridine receptor ap-
pears to be unchanged between normal, mdx leg and
mdx toe microsomes (Fig. 2a). This demonstrates that
the different expression levels of utrophin and dystro-
phin-associated glycoproteins in the proximal versus dis-
tal limb muscles of the mdx mouse model are not an
artefact of the membrane isolation procedure, differential
proteolysis, protein solubilisation, electrophoretic sepa-
ration and/or the immunoblotting technique. 
To investigate whether the above described change in
the expression levels of utrophin and dystrophin-associ-
ated glycoproteins influence the cytopathological status
of mdx toe muscle fibres, a comparative histochemical
analysis was performed. Haematoxylin and eosin stain-
ing clearly revealed the difference between peripheral
muscle fibre nuclei in normal tissue (Fig. 3a) versus cen-
tral muscle fibre nuclei in the mdx leg (Fig. 3b). The ob-
servation that mdx toe fibres show mostly peripheral nu-
clei (Fig. 3c) is in agreement with the notion that the
change in the relative density of dystrophin-associated
glycoproteins might rescue the dystrophic phenotype in
distal muscle groups. This strongly indicates that these
muscle cells, although lacking the dystrophin isoform
Dp427, do not exhibit the same degree of degeneration
seen in mdx leg muscle fibres.
Discussion
In comparison with the established sparing of extraocu-
lar muscles, we can show here that a critical factor in the
prevention of necrosis in distal muscle fibres appears to
be the rescue of dystrophin-associated glycoproteins by a
compensatory over-expression of utrophin. In normal
skeletal muscle fibres, utrophin is highly enriched at the
neuromuscular junction and co-localises with the nico-
tinic acetylcholine receptor complex (Ohlendieck et al.
1991). However, we were able to show previously that
this protein is localised extra-junctionally in mdx fibres
(Matsumura et al. 1992), so utrophin might anchor dys-
trophin-associated glycoproteins in dystrophin-deficient
cells. This in turn might reinstate sarcolemmal integrity
by at least partially re-linking the extracellular matrix to
the actin membrane cystoskeleton and thereby prevent-
ing Ca2+-induced protein degradation. That the endoge-
nous up-regulation of utrophin protects the sarcolemmal
integrity has been demonstrated by severe dystrophic
changes in extraocular mdx-utrn–/– mouse muscle, which
lacks both dystrophin and utrophin (Porter et al. 1998).
The finding that distal mdx muscle groups, although
deficient in dystrophin, exemplify a protected phenotype,
might be of potential significance for both diagnostic
and therapeutic purposes. Due to the complexity of the
clinical manifestation of inherited muscle diseases, cur-
rent molecular DMD diagnostics still give occasionally
ambiguous results (Miller and Hoffman 1994). Novel
strategies for improving the diagnosis of DMD include
systematic newborn creatine kinase screening, extended
genetic testing covering gene duplications, missense 
mutations and stop-codon mutations, besides the more
common deletions of the DMD gene, as well as carrier
testing. Comparing test results for creatine kinase activi-
ty between normal muscle, dystrophic mdx leg fibres
and protected mdx specimens from the extraocular or 
toe region might be helpful in refining this diagnostic 
enzyme procedure. Current therapeutic approaches for
DMD include gene therapy (Hartigan-O’Connor and
Chamberlain 2000), cell therapy (Partridge and Davies
1995) and pharmacological intervention (Badalamente
and Stracher 2000). Important issues for the clinical ap-
plication of gene therapy are the selection of the opti-
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Fig. 3 Histochemical analysis of normal (a), mdx leg (b) and mdx
toe (c) muscle fibres. Shown are 10 µm-thick transverse cryosec-
tions labelled with haematoxylin and eosin. While normal control
muscle fibres (a) and mdx toe cells (c) exhibit almost exclusively
peripheral nuclei, mdx leg muscle fibres show many central nuclei
(b). Counting of histochemically stained nuclei in 30 fibres re-
vealed approximately 10% peripheral nuclei in mdx leg muscle
versus approximately 95% peripheral nuclei in mdx toe cells.
Thus, mdx toe muscle, although lacking the dystrophin isoform
Dp427, does not appear to show the same degree of degeneration
as seen in mdx leg muscle fibres. Bar equals 20 µm
mum delivery system, controlling expression levels
without causing immunological and/or cytotoxic side ef-
fects and how genes can be sufficiently delivered to all
affected cell types (Hartigan-O’Connor and Chamberlain
2000). Potential pharmacological strategies include the
drug-induced up-regulation of compensatory molecules
such as utrophin, the targeted introduction of protease in-
hibitors such as carnitine-linked leupeptin in order to in-
activate Ca2+-dependent calpain activity, and immuno-
suppressive therapy. Especially with respect to the idea
that up-regulation of utrophin prevents dystrophic chang-
es (Rafael et al. 1998), further investigations into the nat-
urally protected distal mdx muscle groups could help in
designing the most favourable gene to be delivered into
DMD muscle, whether that be by adenoviral vectors, in-
travascular delivery of naked DNA or stem cell transfer
therapy.
In conclusion, this report demonstrates that distal mdx
muscle groups represent unique relatively unaffected
skeletal muscle fibres. In contrasting the molecular
pathogenesis of necrotic mdx limb muscle with the ap-
parently protected toe fibres, further more refined inves-
tigations into these phenotypic differences may pave the
way for a more detailed understanding of DMD. Once
compensatory cellular mechanisms are better under-
stood, such pathobiochemical knowledge might help in
developing new treatment strategies for muscular dystro-
phies. It remains to be determined whether other cellular
factors, besides utrophin up-regulation, such as a lower
mechanical stress per unit surface membrane area and/or
metabolic differences, are also involved in the sparing of
distal mdx muscle fibres.
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